(Q38364870)

2 September 2017

1 reference

title

The asthma COPD overlap syndrome (ACOS). (English)

1 reference

2 September 2017

0 references

1 reference

Amit D Parulekar

2

0 references

Nicola A Hanania

series ordinal

4

object named as

Nicola A Hanania

1 reference

2 September 2017

Stephen Bujarski

1

1 reference

2 September 2017

Amir Sharafkhaneh

series ordinal

3

1 reference

2 September 2017

publication date

1 March 2015

1 reference

Current Allergy and Asthma Reports

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

509

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-014-0509-6

2 September 2017

exact match

0 references

cites work

The clinical features of the overlap between COPD and asthma

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Proportional classifications of COPD phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Clinical phenotypes of COPD: identification, definition and implications for guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Complex phenotypes in asthma: current definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Asthma and chronic obstructive pulmonary disease: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Interpretative strategies for lung function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The overlap syndrome of asthma and COPD: what are its features and how important is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

High hospital burden in overlap syndrome of asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Overlap syndrome of asthma and COPD predicts low quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

External validity of randomized controlled trials in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Asthma and cigarette smoking: a review of the empirical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Asthma and smoking status in a population-based study of California adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Characteristics of COPD phenotypes classified according to the findings of HRCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Asthma and irreversible airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Asthma as a risk factor for COPD in a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Smoking and airway inflammation in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Bronchodilator responsiveness in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Bronchodilator reversibility in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The clinical and genetic features of COPD-asthma overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

The multiple dimensions of airways disease: targeting treatment to clinical phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Predictors of response to tiotropium versus salmeterol in asthmatic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Tiotropium bromide step-up therapy for adults with uncontrolled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Improvements with tiotropium in COPD patients with concomitant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Monoclonal antibodies for the treatment of refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Omalizumab for severe asthma: efficacy beyond the atopic patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Towards individualised treatment in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0509-6

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD

21 January 2018

1 reference

12 December 2020

Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes

1 reference

12 December 2020

Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group

1 reference

12 December 2020

Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma.

1 reference

12 December 2020

Eosinophilic airway inflammation in COPD

1 reference

12 December 2020

Spanish guideline for COPD (GesEPOC). Update 2014.

1 reference

12 December 2020

Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease

1 reference

12 December 2020

Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad. Argumentos a favor

1 reference

12 December 2020

Consensus document on the overlap phenotype COPD-asthma in COPD.

1 reference

12 December 2020

Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study

1 reference

12 December 2020

The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly

1 reference

12 December 2020

Airway hyperresponsiveness and COPD mortality

1 reference

12 December 2020

Inhaled budesonide therapy for patients with stable COPD

1 reference

12 December 2020

10.1007/S11882-014-0509-6

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1006426690

0 references

1 reference